VYNE Therapeutics (VYNE) Stock Forecast, Price & News

VYNE Therapeutics (NASDAQ:VYNE) Frequently Asked Questions

Is VYNE Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE Therapeutics stock.
View analyst ratings for VYNE Therapeutics or view top-rated stocks.

When is VYNE Therapeutics' next earnings date?

VYNE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for VYNE Therapeutics.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) issued its quarterly earnings results on Thursday, March, 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.09 million. VYNE Therapeutics had a negative net margin of 444.88% and a negative trailing twelve-month return on equity of 103.25%.
View VYNE Therapeutics' earnings history.

When did VYNE Therapeutics' stock split? How did VYNE Therapeutics' stock split work?

VYNE Therapeutics's stock reverse split on the morning of Tuesday, February 16th 2021. The 1-4 reverse split was announced on Thursday, February 11th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 15th 2021. An investor that had 100 shares of VYNE Therapeutics stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for VYNE?

3 brokerages have issued 12-month target prices for VYNE Therapeutics' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate VYNE Therapeutics' share price to reach $6.50 in the next year. This suggests a possible upside of 1,566.7% from the stock's current price.
View analysts' price targets for VYNE Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VYNE Therapeutics' key executives?

VYNE Therapeutics' management team includes the following people:

• Mr. David T. Domzalski, CEO, Pres & Director (Age 55, Pay $892.07k)
• Dr. Iain A. Stuart Ph.D., Chief Scientific Officer (Age 49, Pay $534.8k)
• Ms. Mutya Harsch J.D., Gen. Counsel, Chief Legal Officer & Company Sec. (Age 47, Pay $559.54k)
• Mr. Tyler Zeronda, CFO, Principal Accounting Officer & Treasurer (Age 36)
• Mr. Raymond G. Steitz, Sr. VP of Global HR (Age 63)
• Dr. Russell Elliott D.Phil., Sr. VP of Pharmaceutical Devel. (Age 56)
• Dr. Darrell S. Rigel M.S., M.D., MS, Consultant (Age 72)

Who are some of VYNE Therapeutics' key competitors?

Some companies that are related to VYNE Therapeutics include Olema Pharmaceuticals (OLMA), DURECT (DRRX), Puma Biotechnology (PBYI), Homology Medicines (FIXX), Trevi Therapeutics (TRVI), Tiziana Life Sciences (TLSA), Entasis Therapeutics (ETTX), IMV (IMV), Equillium (EQ), Capricor Therapeutics (CAPR), Hookipa Pharma (HOOK), Alzamend Neuro (ALZN), Clearside Biomedical (CLSD), Epizyme (EPZM) and Eliem Therapeutics (ELYM).
View all of VYNE's competitors.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), OrganiGram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.63%), Renaissance Technologies LLC (1.72%), State Street Corp (0.36%), Bailard Inc. (0.25%), Beacon Pointe Advisors LLC (0.13%) and Mackenzie Financial Corp (0.12%). Company insiders that own VYNE Therapeutics stock include Andrew Saik, David Domzalski, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends for VYNE Therapeutics.

Which major investors are selling VYNE Therapeutics stock?

VYNE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for VYNE Therapeutics or view top insider-selling stocks.

Which major investors are buying VYNE Therapeutics stock?

VYNE stock was bought by a variety of institutional investors in the last quarter, including Bailard Inc., Beacon Pointe Advisors LLC, Mackenzie Financial Corp, and Renaissance Technologies LLC. Company insiders that have bought VYNE Therapeutics stock in the last two years include Andrew Saik, David Domzalski, Patrick G Lepore, and Perceptive Advisors Llc.
View insider buying and selling activity for VYNE Therapeutics or or view top insider-buying stocks.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $0.39.

How much money does VYNE Therapeutics make?

VYNE Therapeutics has a market capitalization of $22.58 million and generates $14.76 million in revenue each year. The company earns $-73.33 million in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does VYNE Therapeutics have?

VYNE Therapeutics employs 28 workers across the globe.

What is VYNE Therapeutics' official website?

The official website for VYNE Therapeutics is www.menlotherapeutics.com.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company can be reached via phone at (800) 755-7936 or via email at [email protected].